i
Indication
Asthma moderate to severe
Case Studies
Clinical Trial Performed in Asthma
III
Study phase
30
Target patient population
12
Number of sites
NO
Active screening
4
Screening period
(months)
88
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in COPD
i
Indication
COPD
III
Study phase
55
Target patient population
10
Number of sites
NO
Active screening
3
Screening period
(months)
101
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Heart Failure
i
Indication
Heart Failure NYHA IV
III
Study phase
365
Target patient population
22
Number of sites
NO
Active screening
18
Screening period
(months)
392
Number of patients randomised
Type of service provided
feasibility, site selection, project management, clinical monitoring
Clinical Trial Performed in Thrombo-Embolic Events
i
Indication
Profilaxy in Thrombo Embolic Events
III
Study phase
100
Target patient population
38
Number of sites
NO
Active screening
36
Screening period
(months)
848
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Dialysis
i
Indication
End Stage Dialysis patients
III
Study phase
50
Target patient population
10
Number of sites
NO
Active screening
6
Screening period
(months)
117
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Pre-Renal Anemia
i
Indication
Pre-Renal Anemia
III
Study phase
40
Target patient population
10
Number of sites
NO
Active screening
6
Screening period
(months)
74
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Breast Cancer
i
Indication
Breast Cancer
III
Study phase
30
Target patient population
4
Number of sites
NO
Active screening
6
Screening period
(months)
47
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Multiple Sclerosis
i
Indication
Remitting Remissive Multiple Sclerosis
III
Study phase
12
Target patient population
7
Number of sites
NO
Active screening
45
Screening period
(months)
29
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Prostatic Cancer
i
Indication
Prostatic Cancer Testosterone dependent
III
Study phase
25
Target patient population
9
Number of sites
NO
Active screening
4
Screening period
(months)
38
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Diabetes Mellitus
i
Indication
Decompensated Diabetes Mellitus
III
Study phase
40
Target patient population
10
Number of sites
NO
Active screening
3
Screening period
(months)
71
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Clinical Trial Performed in Osteoporosis
i
Indication
Osteoporosis in postmenopausal female
III
Study phase
50
Target patient population
12
Number of sites
NO
Active screening
9
Screening period
(months)
117
Number of patients randomised
Type of service provided
feasibility, site selection, organizing IM, project management, clinical monitoring, regulatory affairs
Marketing Authorization
CTC was involved in clinical trials with drugs that received FDA and EMA marketing authorization
Gileny
sphingosine 1-phosphate receptor modulator for multiple sclerosis (first in class)
Galvus
Inhibitor of dipeptidyl peptidase for diabetes mellitus